Early detection of irreversibly damaged ischemic tissue by flumazenil positron emission tomography in cats

Stroke

Volumn 28, Issue 10, 1997, Pages 2045-2052

  Heiss, Wolf Dieter ^a   Graf, Rudolf ^a   Fujita, Toshiaki ^a   Ohta, Kouichi ^a   Bauer, Bernd ^a   Löttgen, Jan ^a   Wienhard, Klaus ^a  

^a MAX PLANCK INSTITUTE FOR NEUROLOGICAL RESEARCH   (Germany)

Author keywords

Cats; Cerebral blood flow; Cerebral ischemia, focal; Flumazenil; Neuronal damage; Positron emission tomography; Receptors, benzodiazepine

Indexed keywords

BENZODIAZEPINE RECEPTOR; CARBON 11; FLUMAZENIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN BLOOD FLOW; BRAIN ISCHEMIA; BRAIN OXYGEN CONSUMPTION; BRAIN SCINTISCANNING; CAT; DRUG RECEPTOR BINDING; EARLY DIAGNOSIS; FEMALE; GLUCOSE METABOLISM; ISOTOPE LABELING; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

EID: 0030671284     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.28.10.2045     Document Type: Article

References (53)

1. Astrup J, Siesjö BK, Symon L. Thresholds in cerebral ischemia: the ischemic penumbra. Stroke. 1981;12:723-725.
2. Heiss W-D, Graf R. The ischemic penumbra. Curr Opin Neurology. 1994;7:11-19.
3. Baron JC, Rougemont D, Soussaline F, Bustany P, Crouzel C, Bousser MG, Comar D. Local interrelationships of cerebral oxygen consumption and glucose utilization in normal subjects and in ischemic stroke patients: a positron tomography study. J Cereb Blood Flow Metab. 1984;4:140-149.
4. Powers WJ, Grubb RL Jr, Darriet D, Raichle ME. Cerebral blood flow and cerebral metabolic rate of oxygen requirements for cerebral function and viability in humans. J Cereb Blood Flow Metub. 1985;5:600-608.
5. Baron JC, Bousser MG, Rev A, Guillard A, Comar D, Castaigne P. Reversal of focal 'misery-perfusion syndrome' by extra-intracranial arterial bypass in hemodynamic cerebral ischemia. Stroke. 1981;12: 454-459.
6. Heiss W-D, Fink GR, Huber M, Herholz K. Positron emission tomography imaging and the therapeutic window. Stroke. 1993; 24(suppl I):I-50-I-53.
7. Furlan M, Marchai G, Viader F, Derlon J-M, Baron J-C, Spontaneous neurological recovery after stroke and the fate of the ischemic penumbra. Ann Neurol. 1996;40:216-226.
8. Sette G, Baron JC, Young AR, Miyazawa H, Tillet I, Barré L, Travère JM, Derlon JM, MacKenzic ET. In vivo mapping of brain benzodiazepine receptor changes by positron emission tomography after focal ischemia in the anesthetized baboon. Stroke. 1993;24: 2046-2058.
9. Savic I, Ingvar M, Stone-Elander S. Comparison of (11C)flumazenil and (18F)FDG as PET markers of epileptic foci. J Neurol Neurosurg Psychiatry. 1993;56:615-621.
10. Henry TR, Frey KA, Sackellares JC, Gilman S, Koeppe RA, Brunberg JA, Ross DA, Berent S, Young AB, Kuhl DE. In vivo cerebral metabolism and central benzodiazepine-receptor binding in temporal lobe epilepsy. Neurology. 1993;43:1998-2006.
11. Sadzot B, Debets RM, Delfiore G, van Huffelen CW, van Veelen AC, Degueldre C, Comar D, Franck G Decrease of 11C-flumazenil binding is more localized than glucose hypometabolism in patients with TLE studied by PET. Neurology. 1994;44(suppl 2):A351-A352.
12. Szelies B, Weber-Luxenburger G, Pawlik G, Kessler J, Holthoff V, Mielke R, Herholz K, Bauer B, Heiss W-D. MRI-guided flumazenil- and FDG-PET in temporal lobe epilepsy. Neuroimage. 1996;3:109-118.
13. Nakagawara J, Sperling B, Lassen NA. Incomplete brain infarction of reperfused cortex may be quantitated with iomazenil. Stroke. 1997;28:124-132.
14. Hatazawa J, Satoh T, Shimosegawa E, Okudera T, Inugami A. Ogawa T, Fujita H, Noguchi K, Kanno I, Miura S, Murakami M, Iida H, Miura Y, Uemura K. Evaluation of cerebral infarction with iodine-123-iomazenil SPECT. J Nucl Med. 1995;36:2154-2161.
15. Heiss W-D, Graf R, Löttgen J, Ohta K, Fujita T, Wagner R, Grond M, Wienhard K. Repeat positron emission tomographic studies in transient middle cerebral artery occlusion in cats: residual perfusion and efficacy of postischemic reperfusion. J Cereb Blood Flow Metab. 1997;17:388-400.
16. Herbert DA, Mitcheli RA. Blood gas tensions and acidic balance in awake cats. J Appl Physiol. 1971;30:434-436.
17. Graf R, Kataoka K, Rosner G, Heiss W-D. Cortical deafferentation in cat focal ischemia: disturbance and recovery of sensory functions in cortical areas with different degrees of CBF reduction. J Cereb Blood Flow Metab. 1986;6:566-573.
18. Reinoso-Suárez F. Topographischer Hirnatlas der Katze. Darmstadt. Germany: E Merck AG; 1961.
19. Mintun MA, Raichle ME, Martin WRW, Herscovitch P. Brain oxygen utilization measured with O15 radiotracers and positron emission tomography. J Nucl Med. 1984;25:177-187.
20. Herscovitch P, Markham J, Raichle ME. Brain blood flow measured with intravenous H2-15O, I: theory and error analysis. J Nucl Med. 1983;24:782-789.
21. Reivich M. Kuhl D, Wolf A, Greenhera J, Phelps M, Ido T, Casella V, Fowler J, Hoffman E, Alavi A, Som P, Sokoloff L. The (18F)fluorodeoxyglucose method for the measurement of local cerebral glucose utilization in man. Circ Res. 1979;44:127-137.
22. Heiss W-D, Graf R, Wienhard K, Löttgen J, Saito R, Fujita T, Rosner G, Wagner R. Dynamic penumbra demonstrated by sequential multitracer PET after middle cerebral artery occlusion in cats. J Cereb Blood Flow Metab. 1994;14:892-902.
23. Wienhard K, Pawlik G, Herholz K, Wagner R, Heiss W-D. Estimation of local cerebral utilization by positron emission tomography of (18F)-2-fluoro-2-deoxy-D-glucose: a critical appraisal of optimization procedures. J Cereb Blood Flow Metab. 1985;5:115-125.
24. Baron JC, Frackowiak RSJ, Herholz K, Jones T, Lammertsma AA, Mazoyer B, Wienhard K. Use of PET methods for measurement of cerebral energy metabolism and hemodynamics in cerebrovascular disease. J Cereb Blood Flow Metab. 1989;9:723-742.
25. Frey KA, Holthoff VA, Koeppe RA, Jewett DM, Kilbourn MR, Kuhl DE. Parametric in vivo imaging of benzodiazepine receptor distribution in human brain. Ann Neurol. 1991;30:663-672.
26. Wienhard K, Dahlbom M, Eriksson L, Michel Ch, Bruckbauer T, Pietrzyk U, Heiss W-D. The ECAT EXACT HR: performance of a new high resolution positron scanner. J Comput Assist Tomogr. 1994;18:110-118.
27. Eriksson L, Holte S, Bohm C, Kesselberg M, Hovander B. Automated blood sampling systems for positron emission tomography. IEEE Trans Nucl Sci. 1988;35:703-704.
28. Müller WE. The Benzodiazepine Receptor. Cambridge, England: Cambridge University Press; 1987.
29. Hantraye P, Kaijima M, Prenant C, Guibert B, Sastre J, Crouzel M, Naquet R, Comar D, Mazière M. Central type benzodiazepine binding sites: a positron emission tomography study in the baboons brain. Neurosci Lett. 1984;48:115-117.
30. Abadie P, Baron JC. In vivo studies of the central benzodiazepine receptors in the human brain with positron emission tomography. In: Diksic M, Reba RC, eds. Radiopharmaceuticals and Brain Pathology Studies with PET and SPECT. Boca Raton, Fla: CRC Press: 1991;357-379.
31. Lassen NA. Incomplete cerebral infarction: focal incomplete ischemic tissue necrosis not leading to emollision. Stroke. 1982;13: 522-523.
32. Garcia JH, Lassen NA, Weiller C, Sperling B, Nakagawara J. Ischemic stroke and incomplete infarction. Stroke. 1996;27:761-765.
33. Onodera H, Sato G, Kogure K. GABA and benzodiazepine receptors in the gerbil brain after transient ischemia: demonstration by quantitative receptor autoradiography. J Cereb Blood Flow Metab. 1987;7:82-88.
34. Innis R, Al-Tikriti M, Zohgbi S, Baldwin RM, Sybirska EH, Laruelle MA, Malison RT, Seibyl JP, Zimmermann RC, Johnson EW, Smith EO, Charney DS, Heninger GR, Woods SW, Hoffer PB. SPECT imaging of the benzodiazepine receptor: feasibility of in vivo potency measurements from stepwise displacement curve. J Nucl Med. 1991;32:1754-1761.
35. Hayashida K, Hirose Y, Tanaka Y, Miyashita K, Ishida Y, Miyake Y, Nishimura T. Reduction of 123I-iomazenil uptake in haemodynamically and metabolically impaired brain areas in patients with cerebrovascular disease. Nucl Med Commun. 1996;17:701-705.
36. Al-Tikriti MS, Dey HM, Zoghbi SS, Baldwin RM, Zea-Bonce Y, Innis RB. Dual-isotope autoradiographic measurement of regional blood flow and benzodiazepine receptor availability following unilateral middle cerebral artery occlusion. Eur J Nucl Med. 1994;21: 196-202.
37. Matsuda H, Tsuji S, Kuji I, Shiba K, Hisada K, Mori H. Dual-tracer autoradiography using 125I-iomazenil and 99Tcm-HMPAO in experimental brain ischaemia. Nucl Med Commun. 1995;16: 581-590.
38. Minoshima S, Frey KA, Koeppe RA, Chimowitz MI, McCune WJ, Kuhl DE. Regional discordance between benzodiazepine receptor distribution and glucose metabolism in ischemic cerebral vascular diseases. J Nucl Med. 1993;34:207P.
39. Garcia JH, Mitchem HL, Briggs L, Morawetz R, Hudetz AG, Hazelrig JB, Halsey JH, Conger KA, Transient focal ischemia in subhuman primates: neuronal injury as a function of local cerebral blood flow. J Neuropathol Exp Neurol. 1983;42:44-60.
40. Garcia JH, Wagner S, Liu K-F, Hu X-J. Neurological deficit and extent of neuronal necrosis attributable to middle cerebral artery occlusion in rats: statistical validation. Stroke. 1995;26:627-635.
41. Brierley JB, Prior PF, Calverley J, Jackson SJ, Brown AW. The pathogenesis of ischaemic neuronal damage along the cerebral arterial boundary zones in Papio anubis. Brain. 1980;103:929-965.
42. Bowery NG, Wong EHF, Hudson AL. Quantitative autoradiography of (3H)-MK-801 binding sites in mammalian brain. Br J Pharmacol. 1988;93:944-954.
43. Brown CM, Kilpatrick AT, Martin A, Spedding M. Cerebral ischaemia reduces the density of 5-HT2 binding sites in the frontal cortex of the gerbil. Neuropharmacology. 1988;27:831-836.
44. Westerberg E, Monaghan DT, Cotman CW, Wieloch T. Excitatory amino acid receptors and ischemic brain damage in the rat. Neurosci Lett. 1987;73:119-124.
45. Dewar D, Wallace MC, Kurumaji A, McCulloch J. Alterations in the N-methyl-D-aspartate receptor complex following focal cerebral ischemia. J Cereb Blood Flow Metab. 1989;9:709-712.
46. Schwartz RD, Yu X, Wagner J, Ehrmann M, Mileson BE. Cellular regulation of the benzodiazepine/GABA receptor: arachidonic acid, calcium, and cerebral ischemia. Neuropsychopharmacology. 1992;6:119-125.
47. Pappata S, Fiorelli M, Rommel T, Hartmann A, Dettmers C, Yamaguchi T, Chabriat H, Poline JB, Crouzel C, DiGiamberardino L, Baron JC. PET study of changes in local brain hemodynamics and oxygen metabolism after unilateral middle cerebral artery occlusion in baboons. J Cereb Blood Flow Metab. 1993;13:416-424.
48. Holthoff VA, Koeppe RA, Frey KA, Paradise AH, Kuhl DE. Differentiation of radioligand delivery and binding in the brain: validation of a two-compartment model for (11C)flumazenil. J Cereb Blood Flow Metab. 1991;11:745-752.
49. Persson A, Pauli S, Halldin C, Stone-Elander S, Farde L, Sjogren I, Sedvall G. Saturation analysis of specific (11C)Ro 15 1788 binding to the human neocortex using positron emission tomography. Hum Psychopharmacol. 1989;4:21-31.
50. Abadie P, Baron JC, Bisserbe JC, Boulenger JP, Rioux P. Travère JM, Barré L, Petit-Taboué MC, Zarifian E. Central benzodiazepine receptors in human brain: estimation of regional Bmax and Kd values with positron emission tomography. Eur J Pharmacol. 1992; 213:107-115.
51. Olsen RW. The GABA postsynaptic membrane receptor-ionophore complex. Mol Cell Biochem. 1981;39:261-279.
52. Abi-Dargham A, Lauruelle M, Seibyl J, Rattner Z, Baldwin RM, Zoghbi SS, Zea-Ponce Y, Bremner JD, Hyde TM, Charney DS, Hoffer PB, Innis RB. SPECT measurement of benzodiazepine receptors in human brain with iodine-123-iomazenil: kinetic and equilibrium paradigms. J Nucl Med. 1994;35:228-238.
53. Koeppe RA, Holthoff VA, Frey KA, Kibourn MR. Kuhl DE. Compartmental analysis of [11C)flumazenil kinetics for the estimation of ligand transport rate and receptor distribution using positron emission tomography. J Cereb Blood Flow Metab. 1991;11:735-744.